EC grants marketing authorisation to afatinib in SqCC of the lung
The European Commission (EC) has approved Boehringer Ingelheim’s Giotrif (afatinib) for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung. Specifically, afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy.
Click on this link for more information.
